story of the week
Improved Survival in Ovarian Cancer With Veliparib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Veliparib With First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
N. Engl. J. Med 2019 Sep 28;[EPub Ahead of Print], RL Coleman, GF Fleming, MF Brady, EM Swisher, KD Steffensen, M Friedlander, A Okamoto, KN Moore, N Efrat Ben-Baruch, TL Werner, NG Cloven, A Oaknin, PA DiSilvestro, MA Morgan, JH Nam, CA Leath, S Nicum, AR Hagemann, RD Littell, D Cella, S Baron-Hay, J Garcia-Donas, M Mizuno, K Bell-McGuinn, DM Sullivan, BA Bach, S Bhattacharya, CK Ratajczak, PJ Ansell, MH Dinh, C Aghajanian, MA BookmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.